Lista de obras -

A high‐dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio

artículo científico publicado en 2023

A model for the determination of pollen count using google search queries for patients suffering from allergic rhinitis.

artículo científico

A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids

artículo científico publicado en 2023

Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper.

artículo científico publicado en 2017

Allergen-Immuntherapie in der aktuellen Covid-19-Pandemiea, b, c

scientific article published on 08 May 2020

Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App

scientific article published on 29 January 2020

Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air<sup>®</sup>approach

artículo científico publicado en 2023

Dose escalation using carbamylated monomeric tree pollen drops is well tolerated in patients with allergic rhinoconjunctivitis and points towards clinical effects

scientific article published on 07 July 2019

EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma

scientific article published on 01 May 2019

Ectoine lozenges in the treatment of acute viral pharyngitis: a prospective, active-controlled clinical study

artículo científico publicado en 2019

Ectoine-Containing Inhalation Solution versus Saline Inhalation Solution in the Treatment of Acute Bronchitis and Acute Respiratory Infections: A Prospective, Controlled, Observational Study

artículo científico publicado en 2019

Improvement of daily allergy control by sublingual immunotherapy: A <scp>MASK</scp>‐air® study

artículo científico publicado en 2023

Inadequate knowledge of allergen immunotherapy among athletes with allergic rhinitis: A post hoc analysis

scientific article published on 24 June 2019

Management of patients with chronic rhinosinusitis during the COVID-19 pandemic - An EAACI Position Paper

artículo científico publicado en 2020

Meta-analysis of the efficacy of ectoine nasal spray in patients with allergic rhinoconjunctivitis

artículo científico publicado en 2014

Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology.

artículo científico publicado en 2017

Personalized Medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model

artículo científico publicado en 2020

Position Paper on the Standardization of Nasal Allergen Challenges.

artículo científico publicado en 2018

RCAT reflects symptom control and quality of life in allergic rhinoconjunctivitis patients

artículo científico publicado en 2017

Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy

artículo científico publicado en 2018

Response to Correspondence to “Short‐course subcutaneous treatment with <scp>PQ</scp> Grass strongly improves symptom and medication scores in grass allergy”

artículo científico publicado en 2024

Short-course of grass allergen peptides immunotherapy over three weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without Asthma: A randomized, multicenter, double-blind, placebo-controlled trial.

artículo científico publicado en 2018

Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy

artículo científico publicado en 2023

The role of mobile health technologies in allergy care: An EAACI position paper

artículo científico publicado en 2019

Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis

artículo científico publicado en 2017

Update about Oralair® as a treatment for grass pollen allergic rhinitis

artículo científico publicado en 2022

Lista de obras de

A high‐dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio

A model for the determination of pollen count using google search queries for patients suffering from allergic rhinitis.

A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids

Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper.

Allergen-Immuntherapie in der aktuellen Covid-19-Pandemiea, b, c

Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App

Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air<sup>®</sup>approach

Dose escalation using carbamylated monomeric tree pollen drops is well tolerated in patients with allergic rhinoconjunctivitis and points towards clinical effects

EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma

Ectoine lozenges in the treatment of acute viral pharyngitis: a prospective, active-controlled clinical study

Ectoine-Containing Inhalation Solution versus Saline Inhalation Solution in the Treatment of Acute Bronchitis and Acute Respiratory Infections: A Prospective, Controlled, Observational Study

Improvement of daily allergy control by sublingual immunotherapy: A <scp>MASK</scp>‐air® study

Inadequate knowledge of allergen immunotherapy among athletes with allergic rhinitis: A post hoc analysis

Management of patients with chronic rhinosinusitis during the COVID-19 pandemic - An EAACI Position Paper

Meta-analysis of the efficacy of ectoine nasal spray in patients with allergic rhinoconjunctivitis

Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology.

Personalized Medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model

Position Paper on the Standardization of Nasal Allergen Challenges.

RCAT reflects symptom control and quality of life in allergic rhinoconjunctivitis patients

Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy

Response to Correspondence to “Short‐course subcutaneous treatment with <scp>PQ</scp> Grass strongly improves symptom and medication scores in grass allergy”

Short-course of grass allergen peptides immunotherapy over three weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without Asthma: A randomized, multicenter, double-blind, placebo-controlled trial.

Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy

The role of mobile health technologies in allergy care: An EAACI position paper

Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis

Update about Oralair® as a treatment for grass pollen allergic rhinitis